PubMed Trending Research Digest — June 09, 2026

A curated digest of 96 trending PubMed articles, automatically categorised and summarised across 25 research areas.

Jump to category

Cancer imaging & radiomics for prognosis Pan-cancer biomarkers & immunogenomics Tumor evolution & genomic instability Cancer therapeutic resistance & chromatin/epigenetic mechanisms Novel genome engineering & RNA-targeted cancer killing Cancer immunotherapy & immune cell biology Cancer targeted therapeutics & molecular drug design Cancer clinical trials & real-world oncology care Cancer microbiome & drug metabolism Neurodegeneration (Alzheimer’s/Parkinson’s) mechanisms & biomarkers Neurodegeneration therapeutics & experimental models Neuroimmune & neurovascular mechanisms (BBB, inflammation, sleep) Neurology epidemiology & risk factors (trauma, aging, social determinants) Cardiometabolic therapeutics (GLP-1/GIP/dual agonists, obesity, diabetes) Cardiovascular & metabolic risk, prevention & clinical outcomes Inflammation, immune regulation & infectious disease Autoimmunity & inflammatory bowel disease / immune-mediated disease Respiratory & pulmonary disease (vaccines, NENs, COPD) Reproductive & maternal-child health (pregnancy, allergy introduction) Public health policy & implementation (taxes, guidelines, NPIs) Renal & urologic disease (fibrosis, proteinuria, surgery outcomes) Musculoskeletal & connective tissue (muscle, bone, osteoporosis, pain syndromes) Hematology & gene-edited cell therapy Ophthalmology & vision outcomes Dermatology/lymphatic disorders & pain

Automated digest · 96 articles · 25 research areas · June 09, 2026

Overview

Across this week’s digest, a dominant theme is precision stratification—using biomarkers, imaging, and molecular signatures to predict prognosis and treatment response. In oncology, PSMA PET/CT radiomics (threshold-tuned) and immunogenomic classifiers (ImmPred) aim to better identify high-risk disease and immune checkpoint blockade responders, while single-cell analyses of copy-number alteration diversity clarify how genomic instability fuels evolution and resistance. In neurodegeneration, multiple studies refine plasma p-tau217 interpretation (including age-related “intermediate zones”), compare p-tau isoforms for differential diagnosis, and link cognitive variability or plasma biomarker profiles to Alzheimer’s trajectories—highlighting a push toward more accurate, earlier, and clinically actionable biomarker frameworks.

A second major thread is mechanism-driven therapeutics and overcoming resistance. Several cancer papers focus on resistance pathways—chromatin looping (RAD21–RAD51), metabolic immune evasion (IL4I1–AHR axis), and lineage switching/EGFR-TKI resistance via SUCLG2—while novel RNA-guided CRISPR-Cas12a2 “trans shredding” expands mutation-agnostic killing strategies. In neurodegeneration, preclinical work targets tau toxicity (FKBP51 inhibition), microglia-mediated early sleep disruption, and GBA1-linked lysosomal/epigenetic control of α-synuclein pathology, reflecting a broader strategy of intervening in upstream disease biology rather than only downstream symptoms.

Finally, the digest shows strong momentum in cardiometabolic and public-health interventions. Multiple phase trials evaluate oral or dual incretin/related agents (GLP-1 and glucagon/GLP-1 combinations) for diabetes and obesity, alongside comparative and combination-effect analyses relevant to cardiovascular risk. Parallel to pharmacology, population and implementation studies—such as SSB tax adoption patterns, pregnancy RSV prevention preferences, and real-world implementation of cognitive NPIs—underscore that effectiveness depends not only on biomedical efficacy but also on policy design, messaging, and standardized clinical thresholds.

Cancer imaging & radiomics for prognosis

[18F] PSMA-3Q PET/CT radiomics at 45% SUVmax threshold: predicting post-surgical ISUP grade ≥ 4 and extraprostatic extension for noninvasive stratification in prostate cancer management.

This retrospective study evaluated [18F] PSMA-3Q PET/CT radiomics in 243 prostate cancer patients undergoing radical prostatectomy, testing SUVmax thresholding at 40%, 45%, and 50% to predict post-surgical ISUP grade ≥4 (psISUP) and extraprostatic extension (EPE). The key finding was that radiomic features derived using an optimal SUVmax threshold-based model (with performance assessed in training vs test cohorts and stratified by PSAD <0.25 vs ≥0.25 ng/mL) enabled noninvasive stratification for both higher-grade disease and EPE. Clinically, this supports using threshold-tuned [18F] PSMA-3Q PET/CT radiomics to better select patients for risk-adapted management without relying solely on post-surgical pathology.

Cui J, Liu Y, Wang G et al. · Cancer imaging : the official publication of the International Cancer Imaging Society · (2026) · View on PubMed ↗ · Free PDF ↗

Pan-cancer biomarkers & immunogenomics

An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.

The study developed an integrated immunogenomic classification (ImmPred) using RNA-seq to predict immune checkpoint blockade (ICB) response and identify subtype-specific therapeutic vulnerabilities across solid tumors. Key findings were that a seven-gene classifier trained on IHC-defined immune phenotypes, integrated with tumor mutational burden (TMB), improved ICB response prediction beyond the immune-inflamed/excluded/desert framework and revealed distinct resistance mechanisms by subtype. This is significant because it provides a more actionable biomarker framework for selecting therapies and targeting vulnerabilities in immunotherapy-treated cancers.

Zhao Y, Wang P, Han Z et al. · EBioMedicine · (2026) · View on PubMed ↗

Integrative single-cell and spatial transcriptomics analysis reveals a baicalein-responsive 10-gene signature for non-small cell lung cancer.

This study analyzed baicalein-responsive gene programs in non-small cell lung cancer (NSCLC) by integrating network pharmacology, single-cell RNA-seq, bulk transcriptomics, spatial transcriptomics, machine learning, and in vitro experiments. It identified a baicalein-responsive 10-gene signature and showed that baicalein targets were enriched in a 32-gene core set, with consensus clustering defining three molecular subtypes based on these programs. The clinical significance lies in providing a potential biomarker/signature for baicalein responsiveness and for stratifying NSCLC tumor microenvironment states at single-cell and spatial resolution.

Wu D, Liu C, Zhan L et al. · Translational oncology · (2026) · View on PubMed ↗

Comprehensive multi-omics pan-cancer analysis revealed that ANTXR1 is a potential biomarker for diagnosis and immunotherapy.

This integrative pan-cancer analysis used multi-omics and clinical datasets (TCGA, GTEx, and public resources) plus single-cell and spatial transcriptomics to define the diagnostic, prognostic, immune, and drug-sensitivity roles of the gene ANTXR1 (TEM8) across cancers, with functional validation in gastric cancer models. The key finding was that ANTXR1 is aberrantly expressed across multiple tumor types and is associated with immune-related features and immunotherapy relevance, and that ANTXR1 functionally contributes to gastric cancer phenotypes in vitro and in vivo. Scientifically and clinically, ANTXR1 is proposed as a pan-cancer biomarker that could help guide diagnosis and immunotherapy stratification.

Qiu Y, Yu Z, Lai W et al. · Biology direct · (2026) · View on PubMed ↗ · Free PDF ↗

Tumor evolution & genomic instability

A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution.

The study performed pan-cancer single-cell analysis of intratumoral copy number alteration (CNA) diversity and evolution in 94 human tumors spanning seven cancer types. Using single-cell copy number profiling (62,646 aneuploid cells) alongside bulk exome sequencing and single-nucleus RNA-seq, it found that increased subclonal diversity correlated with higher CNA burden, whole-genome doubling, and TP53 mutations. This is significant because it clarifies how genomic instability and specific driver events shape evolutionary trajectories within tumors, informing models of progression and treatment resistance.

Ye H, McDonald TO, Elghaish R et al. · Cancer discovery · (2026) · View on PubMed ↗

Cancer therapeutic resistance & chromatin/epigenetic mechanisms

Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer.

This mechanistic cancer biology study used integrated molecular and functional analyses to identify how co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and EGFR-TKI resistance in castration-resistant prostate cancer (CRPC). The authors found that SUCLG2 is a critical driver of neuroendocrine differentiation and resistance, with EGF stimulation inducing SUCLG2 nuclear translocation and formation of a transcriptional complex that promotes TKI-resistant phenotypes. The significance is that dual targeting of EGFR signaling and SUCLG2 may overcome neuroendocrine lineage switching and improve responses to EGFR tyrosine kinase inhibitors in advanced prostate cancer.

Chen WY, Huang KH, Kajla G et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗

Time-resolved proteomic and phosphoproteomic analysis reveals convergent and divergent biological perturbations induced by FDA-approved CDK4/6 inhibitors in hormone receptor-positive breast cancers.

This study used time-resolved quantitative proteomics and phosphoproteomics to compare molecular perturbations induced by FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in hormone receptor-positive (HR+) breast cancer models. Despite shared nominal targets and similar first-line efficacy, the multi-omics profiling revealed convergent and divergent pathway changes across the three drugs. These findings are clinically significant because they provide mechanistic biomarkers for differential cross-line responses and may guide selection of CDK4/6 inhibitor strategy after progression.

Duan SY, Zhai LH, Zhang W et al. · Acta pharmacologica Sinica · (2026) · View on PubMed ↗

PDZK1 disassembles HER2-HSP90 complexes to promote ubiquitin-mediated HER2 degradation and overcome therapy resistance.

This study investigated how PDZK1 regulates HER2 protein stability by disassembling HER2–HSP90 complexes to promote ubiquitin-mediated HER2 degradation, with the goal of overcoming therapy resistance in HER2-positive breast cancer. The key finding is that PDZK1 acts as a tumor suppressor by destabilizing HER2 via HSP90 complex disruption, thereby enhancing HER2 degradation and improving therapeutic responsiveness. These mechanistic insights suggest PDZK1/HSP90/HER2 axis modulation as a potential strategy to counter resistance in HER2-driven breast cancer.

Cao X, Qin C, Guo Y et al. · Journal of advanced research · (2026) · View on PubMed ↗

Cancer-associated and non-neoplastic fibrosis: Comparative mechanisms and emerging antifibrotic strategies.

This review compared mechanisms of fibrosis in non-neoplastic diseases and solid tumors, using idiopathic pulmonary fibrosis as a reference model and focusing on fibrotic tumor contexts such as pancreatic, hepatocellular, colorectal, and triple-negative breast cancers. It highlights conserved pro-fibrotic pathways that drive fibroblast activation, extracellular matrix deposition, and tissue stiffening, and discusses emerging antifibrotic strategies aimed at these shared mechanisms. The synthesis is clinically significant because it frames tumor fibrosis as a therapeutic target for improving immune evasion, drug delivery, and treatment resistance across multiple cancer types.

Riccò B, Grisendi G, Monaco AL et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · (2026) · View on PubMed ↗

RAD21 regulation of the enhancer-promoter chromatin loop of RAD51 promotes PARPi resistance in ovarian cancer.

This study investigated how RAD21 regulates the enhancer–promoter chromatin loop of RAD51 to promote PARPi resistance in ovarian cancer, using an olaparib (PARP inhibitor) Hi-C atlas and an olaparib-resistant ovarian cancer cell line. The key finding was that RAD21-dependent enhancer–promoter looping involving RAD51 contributes to transcriptional and functional changes that drive resistance to olaparib, and that disrupting RAD21 affects ovarian cancer cell behavior and spheroid growth under PARPi pressure. Clinically, the work identifies a chromatin-looping mechanism that could be targeted to overcome PARPi resistance in ovarian cancer.

Gou R, Chang X, Cheng H et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Novel genome engineering & RNA-targeted cancer killing

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding.

The study programmed CRISPR-Cas12a2, an RNA-guided nuclease with trans-nucleolytic cleavage, to target cancer-specific transcripts and induce chromatin shredding in cancer cells. Key findings were that RNA-triggered Cas12a2 trans shredding of chromatin caused DNA damage responses and cell death, providing a mutation-agnostic way to kill tumors even when mutant proteins (e.g., p53-altered in ~40–50% of cases) lack druggable pockets. This work is significant because it expands CRISPR-based therapeutics toward targeting RNA-defined cancer states to drive lethal genome damage rather than restoring specific mutant proteins.

Zeng J, Cheng Z, Chen H et al. · Nature · (2026) · View on PubMed ↗

Cancer immunotherapy & immune cell biology

GPR15-guided CD8+ T regulatory cells control intestinal inflammation.

The study investigated GPR15 as a marker/homing receptor for a subset of intramucosal regulatory CD8+ T cells (CD8+ TIGR) and examined how deleterious GPR15 gene variants affect intestinal inflammation in humans. It found that GPR15-guided CD8+ TIGR cells control intestinal inflammation, and that defective homing caused by deleterious GPR15 variants is associated with severe early-onset inflammatory bowel disease. This is clinically significant because it links a specific immune-homing pathway (GPR15) to IBD severity and suggests potential targets for restoring regulatory T-cell trafficking.

Cui J, Chen Z, Cheng YH et al. · Nature · (2026) · View on PubMed ↗

Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8+ T cell immunity and suppresses tumor growth.

This preclinical study identified ZY-MY-111, a selective small-molecule inhibitor of IL4I1, and tested whether metabolic checkpoint blockade of the IL4I1–AHR tryptophan axis reactivates CD8+ T cell immunity and suppresses tumor growth. ZY-MY-111 inhibited IL4I1-mediated oxidative deamination (IC50 ~1.86 μM), disrupted Trp–AHR signaling, promoted T cell proliferation, and reduced tumor growth. The work is significant because it positions IL4I1 as a therapeutically targetable metabolic immune-evasion node and supports ZY-MY-111 as a candidate immunometabolic anticancer agent.

Li JF, Wang H, Kang L et al. · Acta pharmacologica Sinica · (2026) · View on PubMed ↗

Cancer targeted therapeutics & molecular drug design

Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer.

This preclinical study developed a nanoplatform using red blood cell–derived extracellular vesicles to deliver cisplatin and cetuximab for combined therapy against triple-negative breast cancer (TNBC). The key finding was that RBC-EV–mediated co-delivery enabled immune evasion and improved the effectiveness of cisplatin plus cetuximab, addressing cisplatin chemoresistance and systemic toxicity limitations. This is significant because it suggests a translational drug-delivery strategy to enhance TNBC treatment efficacy by combining targeted antibody therapy with chemotherapy in a biocompatible, potentially autologous format.

Romano M, Musicò A, Tassoni S et al. · Journal of nanobiotechnology · (2026) · View on PubMed ↗

CUL7-mediated KEAP1 ubiquitination promotes the progression of colon cancer via NRF2 signaling.

This study examined the role of CUL7 in colon cancer and tested whether CUL7 promotes tumor progression through KEAP1 ubiquitination and NRF2 signaling. It reported that high CUL7 expression associates with poor patient prognosis, that CUL7 depletion suppresses proliferation/migration while CUL7 overexpression is oncogenic, and that CUL7 interacts with KEAP1 to drive K29- and K48-linked polyubiquitination. The findings are significant because they identify a CUL7–KEAP1–NRF2 axis as a potential therapeutic target to limit oxidative-stress–driven colon cancer progression.

Shi L, Shi F, Zhang Y et al. · Cell death & disease · (2026) · View on PubMed ↗

Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy.

This study used structure-informed medicinal chemistry to design G-quadruplex (G4) stabilizers targeting KRAS proximal promoter G-quadruplexes (KRAS-G4) for KRAS-driven cancer therapy. It identified dehydroevodiamine (DEE) as a KRAS-G4 stabilizer, then rationally designed and synthesized 15 DEE analogues, with compound 7i emerging as a lead candidate based on structural binding mode and improved activity. The significance is that it advances structurally distinct KRAS-G4 ligands as potential targeted therapeutics for KRAS-driven malignancies.

Zhang L, Han K, Wang X et al. · Angewandte Chemie (International ed. in English) · (2026) · View on PubMed ↗

Cancer clinical trials & real-world oncology care

International consensus on axillary staging after neoadjuvant chemotherapy in node-positive breast cancer.

The study developed an international consensus on eligibility thresholds and technical standards for minimally invasive axillary staging methods—targeted axillary dissection (TAD), marked lymph node biopsy (MLNB), and sentinel lymph node biopsy (SLNB)—in node-positive breast cancer responding to neoadjuvant chemotherapy (NAC). The key finding was that there is currently insufficient consensus, prompting structured expert agreement (≥70%) to standardize when and how these techniques should be used after NAC. This is significant for clinical practice because harmonized axillary staging criteria can reduce variability in surgical management and improve selection of patients for less invasive approaches.

Lucocq J, Karakatsanis A, Kirwan C et al. · European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · (2026) · View on PubMed ↗

Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan.

This retrospective observational real-world study used a Japanese administrative claims database to characterize patient characteristics, treatment patterns, and 2-year completion rates among HR+, HER2− early breast cancer patients receiving adjuvant abemaciclib for 2 years. Among 2042 eligible patients, the analysis reported descriptive outcomes including adherence/completion patterns over follow-up. These findings help define how abemaciclib is used in routine practice in Japan and can inform expectations for persistence and implementation of CDK4/6 inhibition in early breast cancer.

Ozaki Y, Urano M, Sekine N et al. · Future oncology (London, England) · (2026) · View on PubMed ↗

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

This retrospective real-world study analyzed HER2 (ERBB2) mutation testing, treatment patterns, and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in France using the Epidemio-Strategy and Medical Economics Lung Cancer database (NCT03848052). The study found substantial regional variation in HER2 testing and characterized how HER2-mutant (HER2m) patients were treated and what clinical outcomes they experienced during 2015–2020 follow-up. These findings are clinically significant because they quantify real-world gaps in identifying HER2m NSCLC patients who may be eligible for emerging HER2-targeted therapies.

Debieuvre D, Macouillard P, Quantin X et al. · Cancer medicine · (2026) · View on PubMed ↗

GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.

This study used a target trial emulation in obese, nondiabetic US adults (TriNetX; Dec 2014–Jun 2025) to evaluate whether glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with the incidence of 13 obesity-associated cancers (OACs). GLP-1RA exposure was associated with a lower risk of OACs compared with matched non-use groups. These findings support a potential cancer-protective effect of GLP-1RAs specifically in obese patients without diabetes, informing risk–benefit considerations for GLP-1RA prescribing in this population.

Hsu AH, Ramirez PT, Chang YH et al. · Annals of oncology : official journal of the European Society for Medical Oncology · (2026) · View on PubMed ↗

Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.

This case report described a patient with chronic lymphocytic leukemia (CLL) involving the central nervous system who also had concurrent multiple sclerosis (MS), treated with CD19-directed CAR T-cell therapy. CAR T-cell treatment induced complete remission of CLL and was associated with marked improvement in MS disease burden. The significance is that it suggests potential immunologic cross-benefits and feasibility of CD19 CAR T therapy in a complex comorbidity setting, warranting further study.

Murphy DJ, El Hussein S, Applebee A et al. · Leukemia & lymphoma · (2026) · View on PubMed ↗

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

This systematic review and meta-analysis evaluated menin inhibitors (MI)-based therapy in adults with relapsed/refractory acute myeloid leukemia (AML), emphasizing subgroups such as NPM1-mutated and KMT2A-rearranged disease. Across 14 included studies (784 treated patients), the pooled overall response rate was 54.6% and pooled complete response rate was 29.3%, with combination regimens (MI plus hypomethylating agent and venetoclax) showing higher complete response rates than some other approaches. The clinical significance is that it quantifies efficacy and supports MI-based combination strategies as a therapeutic option in R/R AML, particularly in genetically defined subsets.

Alhajahjeh A, Beke KE, Grimshaw AA et al. · Leukemia & lymphoma · (2026) · View on PubMed ↗

Cancer microbiome & drug metabolism

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.

This study investigated how gut microbial metabolism affects the therapeutic efficacy of the antiandrogen flutamide against prostate cancer, focusing on bacterial conversion pathways and genes in relevant gut species. The key finding is that gut bacteria metabolize flutamide into FLU-6 (via nitroreduction) and FLU-9 (via acetylation), with E. coli nfsA and nfsB required for nitroreduction and acetyltransferases driving acetylated metabolite formation. Scientifically, it identifies specific microbial enzymes as contributors to endocrine drug resistance, suggesting that targeting these pathways could restore flutamide efficacy.

Li S, Ding H, Wang J et al. · Gut microbes · (2026) · View on PubMed ↗

Neurodegeneration (Alzheimer’s/Parkinson’s) mechanisms & biomarkers

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

This multicenter retrospective autopsy-confirmed brain bank study evaluated clinicopathological correlation, diagnostic accuracy, genetic associations with pathology, and ancestry-related differences in donors from 11 academic brain banks in the UK, US, and Australia. The study found that integrating genetic data improved understanding of Parkinsonian disorder pathology and revealed ancestry-related differences in clinicopathological patterns and diagnostic performance. These findings support the development of more accurate, in vivo–relevant diagnostic frameworks for neurodegenerative movement disorders that account for genetic and ancestry heterogeneity.

Wu LY, du Toit T, Georgiades T et al. · JAMA neurology · (2026) · View on PubMed ↗

Differential associations of plasma biomarkers with Alzheimer’s disease and small vessel disease: A multimodal imaging study.

This multimodal imaging study assessed how plasma biomarkers—ptau217, GFAP, and NfL—relate to Alzheimer’s disease (AD) neurodegeneration and small vessel disease (SVD) burden in 76 memory clinic patients undergoing 3T MRI and cognitive testing. The key finding is that plasma biomarkers show differential associations with SVD measures (e.g., WMH volume, MSMD, fiber density) versus AD-related neurodegeneration markers (e.g., AD-signature cortical thickness and fiber-bundle cross-section). Scientifically, it supports using biomarker profiles to disentangle overlapping AD and vascular contributions to cognition, with validation reported in an additional cohort.

Dewenter A, Bürger K, Janowitz D et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.

This cohort study examined the prevalence and 5–7 year transition of high-risk plasma p-tau217 status in community-dwelling 70-year-olds from the Gothenburg H70 Birth Cohort Study in Sweden (n=1157 at baseline; n=771 at follow-up). High-risk plasma p-tau217 prevalence increased from 3.6% at age 70 to 7.0% at ages 75–77, with 89% remaining low-risk and 4% converting to high-risk over follow-up. The results are important for population-level risk stratification and for anticipating future Alzheimer’s disease biomarker positivity using plasma p-tau217.

Dittrich A, Arslan B, Skillbäck T et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer’s disease: a systematic review and meta-analysis.

This systematic review and meta-analysis synthesized studies comparing plasma phosphorylated tau (p-tau) isoforms—p-tau181, p-tau217, and p-tau231—for differentiating Alzheimer’s disease (AD) from biologically confirmed non-AD neurodegenerative disorders. Across included evidence up to November 30, 2025, the pooled diagnostic performance quantified sensitivity and specificity for each p-tau isoform in the differential diagnosis setting. This is significant because it informs which plasma p-tau biomarkers may best support clinical decision-making as amyloid-targeting therapies increase the need to accurately distinguish AD from other dementias.

Chai L, Zhan Y, Huang Y et al. · Alzheimer’s research & therapy · (2026) · View on PubMed ↗

This mechanistic study investigated how GBA1 regulates lysine acetyltransferase 8 (KAT8)-mediated histone acetylation to control lysosomal function relevant to α-synuclein pathology in Parkinson’s disease models. It found that GBA1 overexpression enhances lysosomal enzyme expression and regulates histone H4 acetylation at K16 via KAT8, promoting lysosome-associated gene expression and lysosomal activity. These results are significant because they connect a major PD genetic risk factor (GBA1) to an epigenetic-lysosomal pathway that may modulate α-synuclein accumulation.

Cao Y, Zhang Z, Gu X et al. · Cell death & disease · (2026) · View on PubMed ↗

PBMC DEG/miRNA biomarkers of TDP-43 pathology in ALS.

This translational pilot study aimed to identify a disease-specific TDP-43-related gene–microRNA (miRNA) signature in peripheral blood mononuclear cells (PBMCs) of ALS patients with diagnostic potential. Using a TDP-43-based rat model of ALS (stereotaxic infusion of full-length TDP-43 into the motor cortex) to derive differentially expressed genes and then mapping to miRNA signatures, the study generated candidate PBMC DEG/miRNA biomarkers linked to TDP-43 pathology. If validated, these minimally invasive PBMC biomarkers could enable earlier ALS diagnosis and improved patient stratification for clinical trials.

Manchinu MF, Congiu M, Massidda M et al. · Neurobiology of disease · (2026) · View on PubMed ↗

Association between phenotypic age acceleration and mortality in patients with chronic obstructive pulmonary disease.

The study investigated whether phenotypic age acceleration (PhenoAgeAccel), a multisystem biological aging biomarker, predicts all-cause and cause-specific mortality in 1,262 adults with chronic obstructive pulmonary disease (COPD) from NHANES (1999–2010, 2015–2018) linked to mortality through 2019. The key finding was that higher PhenoAgeAccel was associated with increased mortality risk after multivariable Cox modeling (details truncated in the abstract). Scientifically and clinically, it suggests PhenoAgeAccel may improve prognostication in COPD beyond chronological age and could support more biologically informed risk stratification.

Cheng H, Lin C, Chen S et al. · Respiratory medicine · (2026) · View on PubMed ↗

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

This longitudinal analysis within the Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study evaluated whether intraindividual cognitive variability (IICV) predicts preclinical and clinical Alzheimer’s disease outcomes in adults with Down syndrome (N=460). Baseline IICV was tested as a predictor of incident mild cognitive impairment/dementia, cognitive decline, and amyloid beta and tau PET outcomes while adjusting for demographics, intellectual disability, APOE ε4, and site. The study is significant because if IICV forecasts amyloid/tau PET changes and conversion, it could serve as a marker of cognitive resilience and early AD-related change in Down syndrome.

Fonseca LM, Lila E, Shojaie A et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

This study measured plasma p-tau217 in amyloid-beta-negative cognitively unimpaired adults using two immunoassays (ALZpath and LUMIPULSE G1200) to determine how aging affects diagnostic interpretation. It found a non-pathological age-related increase in ALZpath plasma p-tau217 and evaluated how age group, APOE genotype, and gender influenced the proportion of results falling into an intermediate diagnostic zone. Clinically, this matters because it refines how clinicians interpret plasma p-tau217 in older Aβ-negative individuals, reducing the risk of misclassification due to normal aging effects.

Mammel AE, Gonzalez-Ortiz F, Mousavi A et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Neurodegeneration therapeutics & experimental models

Zoster Vaccination and Dementia: Interpreting the Signal and Testing the Mechanisms.

This article reviewed observational studies and quasi-experimental natural experiments evaluating whether herpes zoster vaccination (largely the live attenuated zoster vaccine) is associated with subsequent dementia diagnoses in vaccinated populations. The authors report that multiple analyses suggest fewer later dementia diagnoses, but emphasize that the evidence does not prove mechanism and may reflect delayed diagnosis versus true disease prevention. Mechanistic pathways proposed for direct testing include reduced cumulative varicella-zoster virus (VZV) reactivation burden (including recurrent and possibly unrecognized events) and vaccine-driven immune effects on neuroinflammation.

Rouphael N · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · (2026) · View on PubMed ↗

The Use of Statins in Parkinson’s and Alzheimer’s Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence.

This state-of-the-art review studied clinical and preclinical evidence from 2021–2025 on repurposing statins for disease modification in Parkinson’s disease (PD) and Alzheimer’s disease (AD). The key finding is that statins’ pleiotropic actions—on cholesterol metabolism, neuroinflammation, oxidative stress, and protein aggregation—provide biological plausibility, but clinical results across studies remain heterogeneous and sometimes contradictory. The scientific significance is that it frames where evidence is strongest versus where limitations (study design, endpoints, and translational gaps) must be addressed for future trials.

Chiatto LM, Buccarello L, Carota G et al. · Pharmacology research & perspectives · (2026) · View on PubMed ↗

Stable neuronal representations underlie cognitive resilience to Alzheimer’s disease pathology.

This preclinical study examined cognitive resilience to Alzheimer’s disease pathology in 13-month-old TgF344-AD rats versus non-transgenic littermates using Barnes Maze behavioral testing, Neuropixels recordings from ~8,500 neurons during repeated somatosensory stimulation, and postmortem quantification of tau and amyloid. The key finding is that cognitively resilient TgF344-AD rats show stable neuronal representations despite AD pathology, including altered recruitment patterns compared with non-resilient counterparts. Scientifically, it suggests that preserving functional neuronal coding underlies resilience and could inform interventions aimed at maintaining network-level stability in AD.

Chen K, Pineau E, Koletar M et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

The PDE5 inhibitor vardenafil enhances glutamatergic transmission through amyloid-beta and cellular prion protein.

The study tested whether the PDE5 inhibitor vardenafil (VDF) enhances glutamatergic transmission via amyloid-beta (Aβ) and cellular prion protein (PrPC)–dependent mechanisms. The key finding was that VDF activated an Aβ–cellular prion protei(n) pathway and increased excitatory synaptic transmission, supported by biochemical, immunocytochemical, and electrophysiological experiments in neuronal systems (full mechanistic details truncated). This is significant because it links PDE5 inhibition to Aβ/PrPC signaling in regulating synapses, offering a mechanistic rationale for exploring vardenafil-like strategies in cognitive disorders such as Alzheimer’s disease.

Kafi MAA, Passalacqua M, Villa V et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · (2026) · View on PubMed ↗

FKBP51 inhibition by SAFit2 modulates tau pathology and cognitive deficits in PS19 mice.

This preclinical study tested whether inhibiting FKBP51 with the blood-brain-barrier–penetrant small molecule SAFit2 modulates tau pathology and cognitive deficits in PS19 transgenic mice. The key finding was that SAFit2 treatment reduced FKBP51-linked toxic tau oligomer pathology and improved cognitive performance in PS19 mice. These results are significant because they support FKBP51 as a therapeutic target and SAFit2 as a candidate disease-modifying strategy for tau-driven neurodegeneration in Alzheimer’s disease.

Contreras-Marciales A, Mezquite-Garcia D, Verdina LA et al. · Alzheimer’s research & therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Neuroimmune & neurovascular mechanisms (BBB, inflammation, sleep)

Early microglial response to amyloid plaques drives sleep loss in Alzheimer’s disease.

This animal study investigated how early microglial responses to amyloid plaques drive sleep loss in Alzheimer’s disease using APPswe/PSEN1dE9 (APP/PS1) mice across pathology stages. The key finding is that amyloid plaques cause NREM sleep loss that emerges early and does not worsen with increased plaque burden, and that microglial depletion via CSF1R-mediated approaches implicates microglia in the sleep-loss mechanism. Clinically, it highlights microglia as a potential therapeutic target to prevent early sleep disruption in AD.

Constantino NJ, Irmen RE, Lanning MJ et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

This review examined how age-related vascular senescence contributes to blood-brain barrier (BBB) dysfunction in neurodegenerative diseases, focusing on the neurovascular unit components (endothelial cells, pericytes, astrocytes, and microglia). It highlights mechanisms such as endothelial senescence, pericyte loss, mitochondrial dysfunction, and chronic neuroinflammation as drivers of BBB breakdown with downstream neurodegeneration. The synthesis is significant because it frames BBB failure as a mechanistic bridge between vascular aging and neurodegenerative pathology, suggesting vascular-targeted interventions may be therapeutic.

Behl T, Jayabalan K, Ballal S et al. · Molecular neurobiology · (2026) · View on PubMed ↗

Comments to the “Letter to the Editor” for the manuscript titled “Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer’s disease”.

This article is a commentary responding to a prior report on increased inflammasome signaling genes and proteins in selective brain regions during the intermediate stage of Alzheimer’s disease. It discusses how amyloid and tau pathology can release PAMPs/DAMPs that activate inflammasome sensors (NLRP1, NLRP3, AIM2) via ASC speck formation, leading to GSDMD-mediated pyroptosis and proinflammatory cytokine production. The significance lies in refining interpretation of inflammasome involvement in AD staging and emphasizing mechanistic links between neuropathology and innate immune activation.

de Rivero Vaccari JP, Davis DA, Sawaya AP et al. · Brain pathology (Zurich, Switzerland) · (2026) · View on PubMed ↗

Oral microbiota associated with tooth loss and cognitive function in older adults: Evidence from NHANES.

Using NHANES 2011–2012 data, this study analyzed 1,413 adults aged ≥60 years to test associations between tooth loss, cognitive function, and salivary microbiome composition. Salivary microbiome profiles obtained from 661 participants via 16S rRNA sequencing were associated with tooth loss and cognitive outcomes, suggesting microbial genera may mediate or reflect the tooth loss–cognition relationship. These findings provide population-level evidence linking oral microbiota to cognitive decline and motivate microbiome-informed approaches to preserving oral and brain health in older adults.

Wang Z, Pu R, Gao B et al. · Journal of periodontology · (2026) · View on PubMed ↗

Associations Between Cumulative Head Trauma and Self-Reported Parkinsonism and Parkinson’s Disease in Former Soccer Players.

This cross-sectional study examined associations between cumulative head trauma—repetitive head impacts (RHI) from soccer participation and history of traumatic brain injury (TBI) with loss of consciousness (LOC)—and self-reported parkinsonism and Parkinson’s disease (PD) in former soccer players from the Fox Insight cohort. The key finding is that cumulative head trauma may better predict PD risk than evaluating RHI and TBI in isolation, with effects assessed on PD diagnosis and age at diagnosis. Scientifically, it strengthens the rationale for cumulative exposure models of neurodegeneration risk after sports-related brain injury.

Miner AE, Kmiecik MJ, Namburi N et al. · Movement disorders : official journal of the Movement Disorder Society · (2026) · View on PubMed ↗

Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines.

This retrospective cohort study analyzed 24 years of US EHR data from 5,895 individuals with Down syndrome (DS) in a Midwestern health system to characterize cancer prevalence and implications for screening guidelines. The key finding is that, compared with the general population, most solid tumors are less common in DS while leukemia and testicular cancer are more common, even after adjusting for age. Clinically, these prevalence patterns provide evidence to refine DS-specific cancer screening recommendations in US populations.

Fitzpatrick V, Noah A, Rivelli A et al. · Cancer medicine · (2026) · View on PubMed ↗

GPR35 modulates NaV1.9 gating and sensory neuron excitability.

This study investigated which upstream GPCR regulates the voltage-gated sodium channel NaV1.9 in sensory neurons and identified GPR35 as a modulator of NaV1.9 gating and excitability in dorsal root ganglion (DRG) neurons. Using transcriptomics of NaV1.9-expressing neurons, proximity ligation assays, patch-clamp electrophysiology in primary mouse DRG neurons, and a genetic mouse model, the authors established a receptor–channel signaling axis between GPR35 and NaV1.9. The work is significant because it provides a new molecular target (GPR35) for modulating NaV1.9-driven sensory neuron excitability, with potential implications for pain therapeutics.

Theys M, Cruyssen JV, Salvatierra J et al. · British journal of pharmacology · (2026) · View on PubMed ↗

MRGPRX2 as a novel therapeutic target in headache.

This article reviews and synthesizes evidence on mast cell neuroimmune signaling in migraine, focusing on the mast cell receptor Mas-related G protein-coupled receptor X2/B2 (MRGPRX2/B2) and its activation by neuropeptides such as substance P and PACAP. The key finding is that MRGPRX2/B2 is emerging as a mechanistic therapeutic target linking meningeal sensory neuropeptides to mast cell activation and migraine pathophysiology. Targeting the MRGPRX2/B2 pathway could provide a novel strategy to modulate neuroimmune drivers of migraine beyond current standard approaches.

Nematgorgani S, Brandon JM, Dussor G · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · (2026) · View on PubMed ↗

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

This study characterized novel septin multimer autoantibodies in patients with severe motor neuropathy that can mimic lower motor neuron disease (LMND), using immunoprecipitation with mass spectrometry to identify target antigens and validating specificity with cell-based assays, neutralization assays, and knockout models. The key finding was that a distinct septin multimer autoantibody binding pattern on murine teased sciatic nerve fibers corresponded to a clinically relevant autoimmune neuropathy phenotype distinct from classic LMND. Clinically, identifying these autoantibodies can improve diagnostic accuracy and enable earlier immunotherapy consideration in patients whose neuropathy otherwise appears fatal and treatment-ineligible under LMND assumptions.

Arlt FA, Miske R, Appeltshauser L et al. · Brain : a journal of neurology · (2026) · View on PubMed ↗

This multi-country observational study examined how life-course social vulnerability relates to deep clinical phenotypes and brain health in aging and dementia across six Latin American countries, including cognitively unimpaired controls, Alzheimer’s disease (AD), and frontotemporal lobar degeneration (FTLD). Using a life-course questionnaire to derive a social vulnerability index and latent vulnerability profiles, the study linked social vulnerability to differences in cognitive/functional/mental health and dementia severity measures as well as brain health outcomes. The significance lies in showing that social determinants meaningfully shape dementia phenotypes and neurobiological health, supporting more equitable, stratified approaches to dementia care and research.

Farombi T, Azzi T, Legaz A et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Cardiometabolic therapeutics (GLP-1/GIP/dual agonists, obesity, diabetes)

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.

The SOLSTICE phase 2b randomized, double-blind, placebo-controlled trial studied elecoglipron, an oral small-molecule GLP-1 receptor agonist, in adults with type 2 diabetes across multiple countries. The key finding was the trial’s evaluation of elecoglipron’s efficacy, safety, and tolerability versus placebo in this population (with dosing once daily and no food/fluid restrictions). This is significant because it advances an oral GLP-1 receptor agonist candidate for type 2 diabetes, potentially offering an alternative to injectable incretin therapies.

Aroda VR, Davies MJ, Maaske J et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

The ACHIEVE-2 phase 3 multicentre, randomized, non-inferiority, open-label (orforglipron dose-blinded) trial compared orforglipron, an oral non-peptide GLP-1 receptor agonist, with dapagliflozin, an oral SGLT2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin. The key finding was the head-to-head assessment of glycaemic efficacy and safety over 40 weeks in this metformin-treated population. This is significant because it directly informs combination/sequence choices among oral incretin and SGLT2 options for patients who do not reach glycaemic targets on metformin.

Welch M, Forst T, Jia W et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Survodutide Once Weekly for the Treatment of Adults with Obesity.

In a phase 3 double-blind randomized trial, adults with obesity (BMI ≥30 or ≥27 with obesity-related complications, excluding diabetes) were assigned to once-weekly survodutide, a dual glucagon receptor–GLP-1 receptor agonist. Survodutide produced clinically meaningful weight reduction compared with the control arms over the study period. This provides evidence that a glucagon/GLP-1 dual agonist can further address unmet needs in obesity treatment beyond existing GLP-1–based therapies.

le Roux CW, Wharton S, Startseva E et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.

This study used arm-level phase III trial data to model dose-response and estimate clinical equivalence of semaglutide versus tirzepatide for percent weight change in adults with type 2 diabetes (SUSTAIN/STEP vs SURPASS/SURMOUNT-2). The model-based analysis found semaglutide and tirzepatide exhibit distinct dose-response curves but can be mapped to clinically equivalent weight-loss effects across clinically relevant dosing ranges. These results support dose translation between incretin therapies in T2DM and can inform comparative effectiveness and individualized weight-loss planning.

Builes-Montaño CE, Suarez-Rodriguez AF, Alzate-Vinasco MA · Diabetes therapy : research, treatment and education of diabetes and related disorders · (2026) · View on PubMed ↗

Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.

This prospective phase 2 single-arm CHAMPION trial evaluated a response-adapted consolidative therapy (TCT) strategy using PSMA PET/CT–defined residual PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in newly diagnosed metastatic hormone-sensitive prostate cancer patients with ≤10 distant metastases on conventional imaging. The study assessed efficacy and safety of consolidative treatment for PSMA-avid residual resistant clones following ARPI, using PSMA PET/CT to guide response-adapted management. If effective, this approach could improve outcomes by targeting residual PSMA-avid disease after initial ARPI therapy in a low-metastatic-burden mHSPC population.

Pan J, Wang B, Zhu B et al. · European journal of nuclear medicine and molecular imaging · (2026) · View on PubMed ↗

This randomized, double-blind, placebo-controlled phase 3 trial (SYNCHRONIZE-MASLD) tested once-weekly survodutide, a glucagon receptor/GLP-1 receptor dual agonist, in 216 adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD/MASH). The trial evaluated clinical efficacy and safety outcomes in this population after randomization to survodutide versus placebo. If positive, survodutide could provide a pharmacologic option that simultaneously addresses obesity and MASLD-related liver disease progression.

Kaplan LM, Startseva E, le Roux CW et al. · Nature medicine · (2026) · View on PubMed ↗

REIMAGINE 1 was a randomized, double-blind, placebo-controlled phase 3a trial in adults with type 2 diabetes inadequately controlled on diet and exercise, evaluating once-weekly cagrilintide-semaglutide (CagriSema). The key finding was that the fixed-dose combination improved glycaemic outcomes and was assessed for safety/tolerability versus placebo (specific efficacy/safety results are truncated in the abstract). This is clinically important because it supports a new once-weekly dual incretin/amylin-receptor–based regimen for improving diabetes control in patients not at goal on lifestyle alone.

Aroda VR, Buzzetti R, Dalskov SM et al. · The lancet. Diabetes & endocrinology · (2026) · View on PubMed ↗

REIMAGINE 2 was a double-blind, randomized, controlled phase 3 study in people with type 2 diabetes and overweight/obesity comparing once-weekly cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide alone. The key finding was that the fixed-dose combination was evaluated for superior or additive effects on glycaemic control and bodyweight relative to monotherapies (full results truncated). This is significant because it tests whether combining an amylin receptor agonist (cagrilintide) with a GLP-1 receptor agonist (semaglutide) yields better metabolic outcomes than either component alone.

Buse JB, Bajaj HS, Dalskov SM et al. · The lancet. Diabetes & endocrinology · (2026) · 2 citations · View on PubMed ↗

REIMAGINE 3 was a randomized, double-blind, placebo-controlled phase 3a trial in adults with type 2 diabetes assessing CagriSema as an add-on to basal insulin versus placebo. The key finding was that the once-weekly combination was compared for efficacy and safety in a population where basal insulin often leads to inadequate control, weight gain, and hypoglycaemia risk (specific outcomes truncated). Clinically, this directly informs whether CagriSema can improve glycaemic control while potentially addressing weight and hypoglycaemia concerns when used with basal insulin.

Rosenstock J, Billings LK, Gajria R et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.

This randomized, double-blind phase 3 clinical trial studied orforglipron, an oral nonpeptide GLP-1 receptor agonist, added to titrated insulin glargine in adults with type 2 diabetes and inadequate glycemic control. The trial evaluated efficacy and safety over 40 weeks across multiple countries and sites, testing whether the add-on GLP-1 receptor agonist improves outcomes beyond insulin glargine. The significance is that it assesses a new oral incretin-based combination strategy for patients who remain uncontrolled on insulin glargine.

Giorgino F, D’Souza S, Ludwig L et al. · JAMA · (2026) · View on PubMed ↗

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

This phase 3, double-blind, placebo-controlled randomized clinical trial studied once-weekly 9-mg mazdutide (a glucagon and GLP-1 receptor dual agonist) for weight reduction in Chinese adults with obesity (BMI ≥30), including participants with or without type 2 diabetes. The abstract indicates the trial design and dosing (subcutaneous 9-mg mazdutide vs placebo in a 2:1 randomization across 27 hospitals), with efficacy and safety outcomes to be evaluated over the study period. If mazdutide demonstrates clinically meaningful weight loss with acceptable safety, it would support a new anti-obesity pharmacotherapy option tailored to Chinese adults with obesity, including those with type 2 diabetes.

Gao L, Jiang H, Cai H et al. · JAMA · (2026) · 1 citations · View on PubMed ↗

Cardiovascular & metabolic risk, prevention & clinical outcomes

Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke: A Randomized Clinical Trial.

This investigator-initiated, multicenter randomized clinical trial studied reperfusion-guided systolic blood pressure (BP) targeting after successful endovascular therapy for acute ischemic stroke in adults. The key finding was whether intensive, reperfusion-guided systolic BP control improved functional outcomes compared with guideline-recommended BP management, with blinded end point assessment. This is significant because it addresses a major post-reperfusion management uncertainty and could refine BP targets to improve outcomes after thrombectomy.

Camps-Renom P, Guasch-Jiménez M, Álvarez-Cienfuegos J et al. · JAMA neurology · (2026) · View on PubMed ↗

Endothelin-1 overexpression in mice increases vascular Vegfa164 and Vegfa188 alternative splice isoforms via enhanced Khdrbs3 expression.

Using tamoxifen-inducible endothelial-restricted human endothelin-1 (ieET-1) overexpression mice, the authors studied how ET-1–driven vascular injury alters gene expression programs in mesenteric arteries. RNA-sequencing and RT-qPCR showed that ET-1 overexpression increased vascular Vegfa164 and Vegfa188 alternative splice isoforms via enhanced Khdrbs3 expression. This mechanistic link identifies Khdrbs3 as a potential mediator of ET-1–associated vascular remodeling and injury.

Berillo O, Coelho SC, Ferreira NS et al. · Journal of hypertension · (2026) · View on PubMed ↗

This prospective analysis in the China Health and Retirement Longitudinal Study (CHARLS, 2011–2020) evaluated whether the triglyceride-glucose index–body shape index (TyG-ABSI) predicts cardiovascular disease (CVD) and compared its performance with other TyG-related obesity indices in Chinese adults free of CVD at baseline. The key finding was that TyG-ABSI provided meaningful long-term CVD risk stratification and showed incremental prognostic value relative to conventional TyG-based obesity measures in this East Asian population. This is significant because it supports using a combined lipid–glucose–morphology metric to improve CVD prediction in Chinese clinical risk assessment.

Liu X, Yang S, Fu Q et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.

This study investigated echocardiographic markers that distinguish combined postcapillary and precapillary pulmonary hypertension (Cpc-PH) from isolated postcapillary pulmonary hypertension (Ipc-PH) in systemic sclerosis (SSc) patients with heart failure with preserved ejection fraction (SSc-HFpEF), using echocardiography alongside right heart catheterization (RHC) in 147 adults. The authors reported echocardiographic characterization of hemodynamic phenotypes and identified subtype-specific imaging features associated with Cpc-PH versus Ipc-PH. The clinical significance is that better noninvasive differentiation of PH subtypes in SSc-HFpEF could improve risk stratification and guide management without relying solely on invasive RHC.

Sharma P, Jiang H, Liu D · Journal of hematology & oncology · (2026) · View on PubMed ↗

Echocardiographic characterization of combined postcapillary and precapillary pulmonary hypertension in systemic sclerosis with preserved ejection fraction.

This narrative review evaluated evidence on whether combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with sodium-glucose cotransporter-2 (SGLT2) inhibitors produces synergistic, additive, or non-additive cardiometabolic effects in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. The key conclusion was that the two drug classes act through complementary mechanisms and, based on available data, may yield additive or synergistic benefits on cardiometabolic outcomes rather than redundant effects. This is important for clinical practice because it supports guideline-directed combination therapy strategies aimed at reducing cardiovascular risk beyond glucose lowering.

Daoud A, Goldin G, Goren L et al. · Echo research and practice · (2026) · View on PubMed ↗ · Free PDF ↗

Peripheral Artery Disease as a Predictor of Poor In-hospital Outcomes in Patients with Acute Myocardial Infarction.

This retrospective cohort study used the National Inpatient Sample (2018–2021) to determine whether peripheral artery disease (PAD) predicts poor in-hospital outcomes in adults hospitalized with acute myocardial infarction (AMI). After matching and multivariate logistic regression adjustment, PAD was associated with worse in-hospital outcomes compared with AMI patients without PAD. The findings support PAD as a clinically useful risk marker for identifying AMI patients who may benefit from closer monitoring and more aggressive inpatient management.

Alsmairat Y, Kidess G, Sheffeh MA et al. · The American journal of the medical sciences · (2026) · View on PubMed ↗

Deciphering the molecular mechanisms of fluoxetine-induced sexual dysfunction: Evidence from pharmacovigilance, network toxicology, and molecular docking.

This article analyzed real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS, 2004–2025) to assess the association between fluoxetine and sexual dysfunction, and then used network toxicology plus molecular docking to explore mechanisms. The key finding was that disproportionality and time-to-onset analyses identified a signal linking fluoxetine to sexual dysfunction, and target-enrichment/network and docking implicated specific molecular targets/pathways relevant to the adverse effect. Clinically, the work strengthens evidence for fluoxetine-associated sexual dysfunction and provides mechanistic hypotheses that could guide risk mitigation and future therapeutic targeting.

Li J, Wang X, Zhang Y et al. · Progress in neuro-psychopharmacology & biological psychiatry · (2026) · View on PubMed ↗

Fenofibrate attenuates hyperhomocysteinemia-potentiated thrombosis by restoring platelet fatty acid β-oxidation.

This work studied how hyperhomocysteinemia (HHcy) potentiates thrombosis by altering platelet metabolism, using integrated proteomic and lipidomic analyses of platelets. Homocysteine disrupted platelet lipid homeostasis by impairing fatty acid β-oxidation (FAO), reducing coordinated peroxisome–mitochondria metabolic function and thereby promoting platelet activation. The results are important scientifically because they connect HHcy-driven thrombosis risk to a specific metabolic defect (FAO) that could be targeted to reduce thrombotic events.

Han L, Du X, Yan Y et al. · Redox biology · (2026) · View on PubMed ↗

Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.

This prespecified analysis of the VESALIUS-CV randomized trial studied the PCSK9 inhibitor evolocumab in patients with high-risk diabetes but no prior myocardial infarction or stroke. Evolocumab 140 mg every 2 weeks was compared with placebo to prevent first cardiovascular events, using dual primary endpoints including coronary heart disease death and myocardial infarction (and related components). The significance is that it tests whether PCSK9 inhibition reduces first cardiovascular events in a high-risk diabetes population, informing prevention strategies.

Leiter LA, Giugliano RP, Marston NA et al. · Diabetes care · (2026) · View on PubMed ↗

Plasma Aryl Hydrocarbon Receptor Agonist Activity Is Associated With Inflammation and Metabolic Dysregulation in Obesity: A Cross-Sectional Study.

This cross-sectional study assessed plasma aryl hydrocarbon receptor (AhR) agonist activity in 80 non-diabetic participants across weight categories (39 obese, 23 overweight, 18 normal/healthy) to test associations with inflammation and metabolic dysregulation. Using a cell-based luciferase reporter assay for AhR agonist activity, ELISA for plasma AhR, and multiplex Luminex for inflammatory markers, the study found that plasma AhR agonist activity was linked to inflammatory and metabolic abnormalities in obesity. These results are scientifically important because they implicate circulating AhR agonist activity as a potential biomarker and mechanistic contributor to obesity-related inflammation and metabolic dysfunction.

Bahman F, Kochumon S, Al Madhoun A et al. · Diabetes/metabolism research and reviews · (2026) · View on PubMed ↗ · Free PDF ↗

N-Methyl-D-aspartate receptors: structure, signaling and roles in atherosclerosis.

This narrative/overview article synthesized current evidence on N-methyl-D-aspartate receptors (NMDARs)—including non-neuronal NMDARs—covering their structure, signaling, and roles in atherosclerosis. The key finding was that non-neuronal NMDAR activation by glutamate and NMDAR co-agonists may contribute to atherosclerotic processes through distinct receptor properties and downstream inflammatory/vascular signaling pathways. The significance is that it frames NMDARs as potential mechanistic targets for future cardiovascular therapeutics beyond their established roles in the CNS.

Cai J, Luo ZQ, Zhang M et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Inflammation, immune regulation & infectious disease

Extracellular vesicles participate in proteostasis and heat shock adaptation in Plasmodium falciparum.

The authors investigated how extracellular vesicles (EVs) contribute to proteostasis and heat shock adaptation in the malaria parasite Plasmodium falciparum. Using a PfVps60 knockout (PfVps60KO) line to disrupt ESCRT-dependent vesicular trafficking, they found that EV-related pathways are required for coordinated stress resilience during heat shock. This work links EV biogenesis to parasite survival under febrile proteotoxic stress, identifying PfVps60/ESCRT-mediated trafficking as a potential target for antimalarial strategies.

Avalos-Padilla Y, Román-Álamo L, Bouzón-Arnáiz I et al. · Emerging microbes & infections · (2026) · View on PubMed ↗

Activation of HIF2 in Cardiac Vasculature Leads to Arterial Remodeling, Dilation, Thrombosis, and Inflammation, Recapitulating Cardiac Involvement in Kawasaki Disease.

This study examined whether activating HIF2 in the cardiac vasculature drives cardiovascular pathology relevant to Kawasaki disease by using a von Hippel–Lindau/HIF pathway–focused experimental approach. HIF2 activation led to arterial remodeling, dilation, thrombosis, and inflammation, recapitulating key cardiac involvement seen in Kawasaki disease. These findings strengthen the causal role of HIF2 signaling in KD-like coronary pathology and highlight the VHL/HIF axis as a potential therapeutic target.

Escobar B, Menendez-Montes I, Albendea-Gomez T et al. · Circulation · (2026) · View on PubMed ↗

Extracellular Vesicles in Regenerative Dentistry.

This 2026 review studied how extracellular vesicles (EVs) from immune cells, mesenchymal stem cells, dental stem cells, and engineered sources can regulate regenerative processes in orodental and craniofacial tissues. The key finding is that EVs act as paracrine nanoparticles carrying RNAs, metabolites, lipids, and proteins that can coordinate immune modulation, neurogenesis, angiogenesis, and osteogenesis without the risks of cell transplantation. Clinically, this supports EV-based strategies as a promising regenerative dentistry approach, while highlighting the need for further translation of evolving in vivo and early clinical evidence.

Ahmad P, Estrin NE, Miron RJ · Journal of dental research · (2026) · View on PubMed ↗

IFITM1 differentially regulates antibacterial immunity and immunopathology but is dispensable for antiparasitic responses.

This study investigated the role of the interferon-induced transmembrane protein IFITM1 in bacterial versus parasitic immunity using IFITM1 knockout mice challenged with Mycobacterium tuberculosis and Listeria monocytogenes, and with Leishmania major infection. IFITM1 was upregulated in macrophages and PBMCs during active tuberculosis and accumulated in lungs of animals progressing to TB, and IFITM1 deficiency reduced bacterial burden during chronic M. tuberculosis infection while being dispensable for antiparasitic responses. The results identify IFITM1 as a host factor that differentially regulates antibacterial immunopathology (notably in chronic TB), suggesting it could be a target to modulate harmful inflammation without broadly impairing antiparasitic defense.

Poswayo SKL, Ozturk M, Hazra R et al. · Journal of immunology (Baltimore, Md. : 1950) · (2026) · View on PubMed ↗

An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD.

This umbrella review synthesized meta-analytic evidence (PRISMA-guided; PROSPERO pre-registered) on inflammatory biomarkers and their relationship to antidepressant treatment response in major depressive disorder (MDD). The key finding is that multiple inflammatory biomarkers show associations with treatment response, but the evidence is heterogeneous across biomarkers and study designs. Scientifically, this supports inflammation as a potential stratification axis for MDD treatment response while highlighting the need for standardized biomarker panels and prospective validation.

Baxter L, Utulu N, Utulu F et al. · Neuroscience and biobehavioral reviews · (2026) · View on PubMed ↗

Innovative mucosal nanocarrier systems for enhanced immune response against respiratory pathogens.

The study developed biomimetic alveolar macrophage membrane vesicles (AMVs) as a mucosal nanocarrier nanovaccine platform and evaluated immunogenicity and protection in multiple respiratory pathogen models. The key finding was that AMVs were designed to overcome pulmonary surfactant and improve intracellular delivery to alveolar antigen-presenting cells, particularly alveolar macrophages, thereby enhancing immune responses. This supports a macrophage-vesicle–based intrapulmonary vaccination strategy as a potential way to improve efficacy against respiratory pathogens that are limited by lung extracellular and intracellular delivery barriers.

Zhang Z, Chen R, Zhou X et al. · Journal of advanced research · (2026) · View on PubMed ↗

Safety of BNT162b2 COVID-19 Vaccine in Pregnancy: A Systematic Review.

This systematic review synthesized real-world and clinical evidence on the safety of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine in pregnant individuals. Across included studies, pregnancy safety outcomes were reported with heterogenous designs and limited stratification by dose timing and variant period, but the overall evidence base supports that BNT162b2 can be interpreted as not showing major pregnancy-specific safety signals. These findings are clinically important for counseling pregnant patients and for guiding future pregnancy-focused, product-specific vaccine safety surveillance during evolving SARS-CoV-2 variants.

Thoburn E, Giannakoulis VG, Hu T et al. · Infectious diseases and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Bacteroides-derived endocannabinoid-like commendamide attenuates skeletal muscle ferroptosis in vitro: implications for Duchenne muscular dystrophy.

This study examined whether Bacteroides-derived endocannabinoid-like commendamide influences skeletal muscle ferroptosis, analyzing Bacteroides abundance in fecal samples from dystrophic mdx mice and DMD patients and testing commendamide in vitro. The key finding was that commendamide attenuated skeletal muscle ferroptosis-related effects in cell-based assays, aligning with its proposed protective role in Duchenne muscular dystrophy. Scientifically, it links specific gut-microbiota metabolites (from Bacteroides) to ferroptosis modulation, suggesting a potential microbiome-derived therapeutic avenue for DMD.

Di Muraglia N, De Vito M, Panza E et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Autoimmunity & inflammatory bowel disease / immune-mediated disease

Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review.

This study identified a segregating PTK2B variant in a primary biliary cholangitis (PBC) family and tested its functional relevance using knock-in mice. The PTK2B c.1679C>G variant co-segregated exclusively with PBC in affected family members and was absent in unaffected relatives and controls, and the knock-in model induced PBC-like autoimmune features. The scientific significance is that it provides in vivo genetic evidence implicating PTK2B in PBC pathogenesis and supports the variant as a candidate disease-causing driver.

Stamouli E, Trakatelli CM, Sarigianni M et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study.

This retrospective multicenter real-world study evaluated mirikizumab (an IL-23 p19 monoclonal antibody) in adult patients with moderate-to-severe ulcerative colitis treated at five Italian centers (Jun 2024–Oct 2025) with ≥24 weeks follow-up. The study found that mirikizumab achieved clinically meaningful week-12 outcomes including clinical remission (pMS ≤2 with rectal bleeding 0) and additional improvements across intestinal ultrasound, endoscopic remission, bowel urgency remission, and fecal calprotectin normalization. These real-world effectiveness and safety data strengthen evidence for mirikizumab’s performance outside clinical trials and help clinicians anticipate response and monitoring targets in routine care.

D’Amico F, Fanizzi F, Dal Buono A et al. · Journal of Crohn’s & colitis · (2026) · View on PubMed ↗

Emerging small molecules for ulcerative colitis: clinical advancements and trial insights.

This narrative review examined emerging small-molecule therapies for ulcerative colitis (UC), focusing on recent clinical advancements and trial insights for drugs targeting specific molecular pathways. It summarizes the evolving pipeline beyond conventional stepwise care (e.g., mesalazine, corticosteroids, immunomodulators) and highlights how emerging agents may address the challenge of achieving consistent, durable responses. The review is significant for clinicians and researchers because it frames which small molecules are most promising and what trial design considerations may influence future UC treatment selection.

Lanzotti C, Fanizzi F, D’Amico F et al. · Expert opinion on emerging drugs · (2026) · View on PubMed ↗

Respiratory & pulmonary disease (vaccines, NENs, COPD)

IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms.

This IASLC expert update reviewed and proposed modifications to the 2021 WHO classification of pulmonary neuroendocrine neoplasms (NENs) based on advances in molecular pathways and histopathologic refinement. The key finding was that the panel’s deliberations resulted in an updated classification framework intended to better stratify neuroendocrine tumor (NET) subtypes and enable subtype-specific therapeutic development. This is significant for clinical practice because it aims to improve diagnostic consistency and guide more precise treatment selection across pulmonary NENs.

Beasley MB, Yatabe Y, Papotti M et al. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · (2026) · View on PubMed ↗

Acute exacerbation of chronic rhinosinusitis: clinical and microbiological perspectives from a Saudi tertiary care center.

This retrospective cohort study investigated acute exacerbations of chronic rhinosinusitis (AECRS) in patients at a Saudi tertiary care center (King Saud University Medical City) and characterized the bacterial profile from middle meatus cultures during exacerbation episodes. It aimed to define AECRS clinical features and compare them across chronic rhinosinusitis (CRS) phenotypes, providing microbiological context for exacerbation biology. The clinical significance is that identifying AECRS-associated bacterial patterns and phenotype differences can improve targeted antimicrobial and management strategies for patients with CRS exacerbations.

Alfallaj R, Almousa H, BinGhaith A et al. · Annals of Saudi medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Reproductive & maternal-child health (pregnancy, allergy introduction)

Egg Allergy Prevalence Before and After Guidelines for Earlier Egg Introduction.

This cross-sectional study estimated changes in egg allergy prevalence among infants aged 11–15 months before versus after guideline updates recommending earlier egg introduction, using two population-based samples recruited with identical methods. The key finding was the observed association between the guideline change and the population prevalence of egg allergy. This is significant because it provides real-world evidence on whether earlier egg introduction guidelines translate into reduced egg allergy burden at the population level.

Koplin JJ, Shifti DM, Soriano VX et al. · JAMA pediatrics · (2026) · View on PubMed ↗

Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings.

This cross-sectional study assessed acceptability and preferences regarding RSV prevention during pregnancy among pregnant individuals in diverse global settings after standardized information about RSV risks and expected benefits. The key finding was that participants’ willingness to choose maternal RSV Prefusion F vaccination versus infant monoclonal antibodies could be measured and compared across settings (detailed results truncated). This is significant for public health implementation because it identifies how messaging and context may influence uptake of the two available RSV prevention strategies.

Favre G, Pfund A, Gerbier E et al. · Vaccine · (2026) · View on PubMed ↗

Early Pregnancy Glycemic Testing for Prediction of Gestational Diabetes Mellitus and Large for Gestational Age Birth Weight.

This prospective observational study in the GO MOMs cohort evaluated whether early pregnancy glycemic testing—blinded 75-g OGTT and continuous glucose monitoring (CGM) at 10–14 weeks—improves prediction of gestational diabetes mellitus (GDM) and large for gestational age (LGA) compared with clinical factors alone. Using these early measurements, the authors developed predictive models for GDM at 24–28 weeks and for LGA, assessing added value of OGTT/CGM metrics. The clinical significance is that earlier, more informative glycemic phenotyping could enable risk stratification and earlier interventions to reduce GDM and adverse birth outcomes.

Diabetes care · (2026) · View on PubMed ↗

Public health policy & implementation (taxes, guidelines, NPIs)

Understanding sugar-sweetened beverage tax implementation globally: a 34-year, population-based observational study in 183 countries.

This 34-year, population-based observational study analyzed global implementation of sugar-sweetened beverage (SSB) taxes from 1990–2024 across 183 countries using aggregated international datasets. The key finding was that the extent and types of SSB taxes implemented varied widely by country and were predicted by national characteristics such as SSB intake, disease burden, and economic development. This is significant for public health policy because it identifies which country-level factors are associated with adoption, informing strategies to accelerate effective SSB taxation.

Loaeza LM, Lara-Castor L, Sharib JR et al. · The Lancet. Global health · (2026) · View on PubMed ↗

Implementing multidomain non-pharmaceutical interventions for preventing cognitive decline in community-dwelling older adults in China: An embedded mixed-methods implementation study of determinants and strategies.

This embedded mixed-methods implementation study evaluated determinants and strategies for implementing the WW-FINGERS multidomain non-pharmaceutical interventions (NPIs) to prevent cognitive decline in community-dwelling older adults in China. Using the Consolidated Framework for Implementation Research (CFIR), data from 42 stakeholders across six communities, and hybrid deductive-inductive analysis with coincidence analysis, the study matched strategies using the ERIC compendium and refined them with a stakeholder panel. The significance is that it provides actionable, real-world implementation guidance for scaling effective cognitive health NPIs in Chinese communities.

Huang Z, Qiu G, Shi C et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Renal & urologic disease (fibrosis, proteinuria, surgery outcomes)

Curcumin Inhibits Renal Fibrosis by Suppressing S100A8/A9-TLR4 Signaling via Gut Microbiota-Derived Short-Chain Fatty Acid in Macrophages.

This study tested whether curcumin (CUR) attenuates renal fibrosis in a murine unilateral ureteral obstruction model and in LPS-stimulated bone marrow–derived macrophages, focusing on S100A8/A9–TLR4 signaling and gut microbiota–derived short-chain fatty acids (SCFAs). CUR significantly reduced renal interstitial fibrosis and collagen deposition and suppressed S100A8/A9–TLR4 signaling in macrophages, with effects linked to SCFAs derived from the gut microbiota. These results suggest a microbiota–metabolite–immune mechanism by which curcumin could be therapeutically useful for chronic kidney disease–associated fibrosis.

Li C, Chen X, Zha W et al. · Molecular nutrition & food research · (2026) · View on PubMed ↗

Association of a 0.85 Ratio of Endoscope-Sheath Diameter Threshold with Infectious Complications after Retrograde Intrarenal Surgery: A Two-Institution Retrospective Cohort Study.

In a two-institution retrospective cohort of adults undergoing retrograde intrarenal surgery (RIRS), the authors evaluated whether the ratio of endoscope-sheath diameter (RESD) predicts postoperative infectious complications. A RESD threshold of 0.85 provided better risk discrimination for infectious complications than the conventional target of <0.75, with RESD associated with Clavien-Dindo–graded infections. This supports using RESD as a practical intraoperative metric to stratify infection risk and potentially guide equipment selection during RIRS.

Chae HK, Shin D, Jeong HC et al. · Journal of endourology · (2026) · View on PubMed ↗

TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.

This narrative review with a clinical illustration examined tyrosine kinase inhibitor (TKI)-associated proteinuria and nephrotic syndrome as adverse events of VEGF-pathway inhibition, focusing on radio-iodine-refractory differentiated thyroid cancer. It describes a case of recurring nephrotic-range proteinuria in a patient sequentially treated with lenvatinib, sorafenib, and cabozantinib, and summarizes trial-reported incidence differences across VEGFR-targeted TKIs. The clinical significance is improved recognition and risk management of renal toxicity during VEGF-targeted TKI therapy in thyroid cancer patients.

Van Damme M, Elzo-Kraemer X, Deman A et al. · Acta clinica Belgica · (2026) · View on PubMed ↗

Musculoskeletal & connective tissue (muscle, bone, osteoporosis, pain syndromes)

Rehmannioside D prevents estrogen-deficiency induced osteoporosis by interacting with c-Jun to dismantle the AP-1 complex and suppress MAPK/NF-κB signaling.

The study investigated rehmannioside D (RD) in estrogen-deficiency–induced osteoporosis models and tested its effects on osteoclastogenesis in bone marrow-derived macrophages (BMDMs). RD suppressed RANKL-induced osteoclast differentiation and function by interacting with c-Jun to dismantle the AP-1 complex and by suppressing MAPK and NF-κB signaling, with target engagement supported by Cellular Thermal Shift Assay. These findings are significant because they identify a mechanistic c-Jun/AP-1–centered pathway through which RD could be developed as a targeted anti-osteoporotic therapy.

Wang Y, Wu J, Liu H et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Hematology & gene-edited cell therapy

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

This Phase 3/long-term follow-up analysis studied exagamglogene autotemcel (exa-cel; exa-cel), a one-time ex vivo CRISPR-Cas9 gene-edited cell therapy, in transfusion-dependent β-thalassemia (TDT) patients aged 12–35 years. The key finding is that after exa-cel infusion, measures of ineffective erythropoiesis and iron homeostasis improved and normalized, extending beyond the primary outcomes of fetal hemoglobin reactivation and transfusion independence. Clinically, this supports durable hematologic benefit and provides mechanistic safety/efficacy context for managing iron and erythropoietic dysregulation in TDT.

Sheth S, Corbacioglu S, de la Fuente J et al. · American journal of hematology · (2026) · View on PubMed ↗

Ophthalmology & vision outcomes

Herpesvirus Retinitis by Immune Status: Clinical Phenotypes and Predictors of Retinal Detachment and Severe Visual Impairment.

This retrospective longitudinal cohort study assessed herpesvirus retinitis phenotypes in relation to immune status and identified predictors of retinal detachment (RD) and severe visual impairment among 120 patients (144 eyes) with acute retinal necrosis (ARN) or cytomegalovirus retinitis (CMVR) screened from 2013–2025. The study found that immune status was associated with distinct clinical manifestations and RD patterns, and multivariable analyses identified factors predicting RD and severe visual impairment. These results can guide risk stratification and treatment intensity decisions for herpesvirus retinitis, potentially improving visual outcomes.

Zou Y, Yang M, Zhang J et al. · Ophthalmology. Retina · (2026) · View on PubMed ↗ · Free PDF ↗

Dermatology/lymphatic disorders & pain

Neuropathic Pain Features in Lipedema Compared to Lymphedema: An Exploratory Cross-Sectional Study.

In an exploratory cross-sectional study of 118 women with lipedema (n=62) or bilateral lower-extremity lymphedema (n=56), the authors assessed pain intensity and neuropathic pain features. Lipedema patients showed different neuropathic pain profiles than lymphedema patients based on painDETECT and LANSS measures. These results suggest neuropathic mechanisms may contribute to lipedema pain and could guide more targeted pain assessment and management.

Pervane S, Uzun Ö · Lymphatic research and biology · (2026) · View on PubMed ↗

Generated automatically on June 09, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.

← All Trending Digests

PubMed Trending Research Digest — June 09, 2026

PubMed Trending Research Digest — June 09, 2026

Overview

Cancer imaging & radiomics for prognosis

[18F] PSMA-3Q PET/CT radiomics at 45% SUVmax threshold: predicting post-surgical ISUP grade ≥ 4 and extraprostatic extension for noninvasive stratification in prostate cancer management.

Pan-cancer biomarkers & immunogenomics

An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.

Integrative single-cell and spatial transcriptomics analysis reveals a baicalein-responsive 10-gene signature for non-small cell lung cancer.

Comprehensive multi-omics pan-cancer analysis revealed that ANTXR1 is a potential biomarker for diagnosis and immunotherapy.

Tumor evolution & genomic instability

A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution.

Cancer therapeutic resistance & chromatin/epigenetic mechanisms

Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer.

Time-resolved proteomic and phosphoproteomic analysis reveals convergent and divergent biological perturbations induced by FDA-approved CDK4/6 inhibitors in hormone receptor-positive breast cancers.

PDZK1 disassembles HER2-HSP90 complexes to promote ubiquitin-mediated HER2 degradation and overcome therapy resistance.

Cancer-associated and non-neoplastic fibrosis: Comparative mechanisms and emerging antifibrotic strategies.

RAD21 regulation of the enhancer-promoter chromatin loop of RAD51 promotes PARPi resistance in ovarian cancer.

Novel genome engineering & RNA-targeted cancer killing

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding.

Cancer immunotherapy & immune cell biology

GPR15-guided CD8+ T regulatory cells control intestinal inflammation.

Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8+ T cell immunity and suppresses tumor growth.

Cancer targeted therapeutics & molecular drug design

Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer.

CUL7-mediated KEAP1 ubiquitination promotes the progression of colon cancer via NRF2 signaling.

Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy.

Cancer clinical trials & real-world oncology care

International consensus on axillary staging after neoadjuvant chemotherapy in node-positive breast cancer.

Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan.

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.

Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Cancer microbiome & drug metabolism

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.

Neurodegeneration (Alzheimer’s/Parkinson’s) mechanisms & biomarkers

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

Differential associations of plasma biomarkers with Alzheimer’s disease and small vessel disease: A multimodal imaging study.

Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.

Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer’s disease: a systematic review and meta-analysis.

Lysine acetyltransferase 8-mediated histone acetylation, regulated by GBA1, is associated with lysosomal function related to α-Synuclein pathology.

PBMC DEG/miRNA biomarkers of TDP-43 pathology in ALS.

Association between phenotypic age acceleration and mortality in patients with chronic obstructive pulmonary disease.

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Age-related increase in plasma p-tau217 in amyloid-beta-negative cognitively unimpaired individuals affects diagnostic interpretation.

Neurodegeneration therapeutics & experimental models

Zoster Vaccination and Dementia: Interpreting the Signal and Testing the Mechanisms.

The Use of Statins in Parkinson’s and Alzheimer’s Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence.

Stable neuronal representations underlie cognitive resilience to Alzheimer’s disease pathology.

The PDE5 inhibitor vardenafil enhances glutamatergic transmission through amyloid-beta and cellular prion protein.

FKBP51 inhibition by SAFit2 modulates tau pathology and cognitive deficits in PS19 mice.

Neuroimmune & neurovascular mechanisms (BBB, inflammation, sleep)

Early microglial response to amyloid plaques drives sleep loss in Alzheimer’s disease.

A Age Related Vascular Senescence: Mystery of Blood-brain Barrier Dysfunction in Neurodegeneration.

Comments to the “Letter to the Editor” for the manuscript titled “Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer’s disease”.

Neurology epidemiology & risk factors (trauma, aging, social determinants)

Oral microbiota associated with tooth loss and cognitive function in older adults: Evidence from NHANES.

Associations Between Cumulative Head Trauma and Self-Reported Parkinsonism and Parkinson’s Disease in Former Soccer Players.

Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines.

GPR35 modulates NaV1.9 gating and sensory neuron excitability.

MRGPRX2 as a novel therapeutic target in headache.

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Social vulnerability shapes deep clinical phenotypes and brain health in aging and dementia across Latin America.

Cardiometabolic therapeutics (GLP-1/GIP/dual agonists, obesity, diabetes)

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.

Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Cardiovascular & metabolic risk, prevention & clinical outcomes

Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke: A Randomized Clinical Trial.

Endothelin-1 overexpression in mice increases vascular Vegfa164 and Vegfa188 alternative splice isoforms via enhanced Khdrbs3 expression.

Predictive value of the triglyceride glucose index-a body shape index (TyG-ABSI) for cardiovascular disease and its comparison with other TyG-related obesity indices: a study based on the China health and retirement longitudinal study (CHARLS) cohort.

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.